Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Kodiak Sciences Inc. (KOD) stock profile

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company that researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer undergoing a Phase IIb/III clinical study for the treatment of wet age-related macular degeneration, diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical-stage product candidates include KSI-501, a bispecific conjugate for treating retinal diseases with an inflammatory component, and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Key facts

SymbolKOD
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOVictor Perlroth
Employees109
HeadquartersPalo Alto, CA, US
IPO2018-10-04
Websitekodiak.com

Explore KOD on Vantafin

  • Kodiak Sciences Inc. Overview
  • Kodiak Sciences Inc. Financials
  • Kodiak Sciences Inc. News
  • Kodiak Sciences Inc. Events
  • Kodiak Sciences Inc. SEC filings
  • Kodiak Sciences Inc. Insider transactions
  • Kodiak Sciences Inc. Transcripts

Frequently asked questions

What does Kodiak Sciences Inc. (KOD) do?
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company that researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer undergoing a Phase IIb/III clinical study for the treatment of wet age-related macular degeneration, diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical-stage product candidates include KSI-501, a bispecific conjugate for treating retinal diseases with an inflammatory component, and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Where is KOD stock listed?
Kodiak Sciences Inc. trades under the ticker KOD on NASDAQ.
How can I research KOD's financials and filings?
Vantafin provides Kodiak Sciences Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the KOD profile.